Profile data is unavailable for this security.
About the company
Lionco Pharmaceutical Group Co.,Ltd. is a China-based company principally engaged in the research and development, production and sales of chemical prescription medicine. The Company's products are mainly categorized in to three areas: parenteral nutrition agents, anti-infectious agents and digestive system agents. The lead product of its parenteral nutrition agents is Glutamine for injection; its anti-infectious agents include Cefodizime sodium for injection and Cefathiamidine for injection, among others; its digestive system agents include Omeprazole Sodium for injection and others. The Company operates its business in domestic market.
- Revenue in CNY (TTM)225.39m
- Net income in CNY-122.17m
- Incorporated2003
- Employees475.00
- LocationLionco Pharmaceutical Group Co LtdMedicine Valley Industrial ParkNo. 16 Medicine Valley Erheng RoadNational Hi-tech Industrial Dvlpmnt ZneSHANNAN 856000ChinaCHN
- Phone+86 8 937830999
- Fax+86 8 937830888
- Websitehttp://www.lingkang.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shanghai MicuRx Pharmaceutical Co Ltd | 109.40m | -497.31m | 3.05bn | 205.00 | -- | 4.66 | -- | 27.91 | -0.759 | -0.759 | 0.167 | 0.9991 | 0.0919 | 0.5886 | 5.18 | 533,680.30 | -41.76 | -- | -45.09 | -- | 81.44 | -- | -454.56 | -- | 7.87 | -- | 0.2914 | -- | 88.31 | -- | -91.16 | -- | -- | -- |
Shanghai Shenqi Pharmactcl Inv Mgt CoLtd | 2.25bn | 60.10m | 3.10bn | 1.43k | 48.66 | 1.39 | -- | 1.38 | 0.1237 | 0.1237 | 4.36 | 4.34 | 0.7002 | 5.48 | 5.73 | 1,574,780.00 | 1.95 | -0.6002 | 2.48 | -0.7417 | 45.89 | 56.64 | 2.79 | -0.9128 | 2.50 | 23.18 | 0.1488 | -- | -2.00 | 4.79 | 17.41 | -11.68 | -25.97 | -- |
ChengDu Sheng Nuo Biotec Co Ltd | 460.12m | 71.98m | 3.12bn | 1.13k | 43.33 | 3.54 | -- | 6.79 | 0.6439 | 0.6439 | 4.11 | 7.88 | 0.3381 | 0.8808 | 4.89 | 407,912.20 | 5.28 | 7.47 | 6.86 | 9.44 | 60.50 | 70.52 | 15.63 | 15.82 | 0.9354 | 13.13 | 0.3124 | 21.83 | 9.93 | 9.37 | 9.08 | 18.69 | 54.71 | -- |
Lionco Pharmaceutical Group Co Ltd | 225.39m | -122.17m | 3.17bn | 475.00 | -- | 3.56 | -- | 14.05 | -0.1714 | -0.1714 | 0.3177 | 1.23 | 0.1389 | 2.99 | 3.03 | 474,502.00 | -7.53 | 0.7396 | -8.58 | 0.9562 | 42.58 | 80.88 | -54.21 | 2.08 | 7.18 | -4.81 | 0.3556 | 521.93 | -31.95 | -34.79 | 22.65 | -- | -33.18 | -- |
Data as of Oct 11 2024. Currency figures normalised to Lionco Pharmaceutical Group Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
Holder | Shares | % Held |
---|---|---|
China Asset Management Co., Ltd.as of 31 Dec 2023 | 4.43m | 0.62% |
Gfund Management Co., Ltd.as of 31 Dec 2023 | 2.00m | 0.28% |
SWS MU Fund Management Co., Ltd.as of 31 Dec 2023 | 1.26m | 0.18% |
Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 27 Jun 2024Source: FactSet Research Systems Inc.